Last updated: March 6, 2024
Sponsor: Samsung Medical Center
Overall Status: Completed
Phase
N/A
Condition
Stroke
Cerebral Ischemia
Treatment
Omapone Peri 724mL or Winuf Peri 654mL
Clinical Study ID
NCT04259307
2019-06-109
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Acute first-ever stroke patients less than 7 days after onset
- more than 19 years old at stroke onset ③ stroke confirmed by brain CT or MRI
- body mass index (BMI) <25 before the comprehensive rehabilitation ⑤ MiniNutritional Assessment < 12 before the comprehensive rehabilitation ⑥Fugl-Meyer assessment < 85 at 7 days after stroke onset
Exclusion
Exclusion Criteria:
- Transient ischemic stroke
- Progressive or unstable stroke
- Pre-existing and active major neurological disease, e.g., spinal cordinjury, Parkinson's disease, et al.
- Pre-existing and active (e.g., on chronic medication) major psychiatricdisease, such as major depression, schizophrenia, bipolar disease ordementia ⑤ Advanced liver, kidney, cardiac, or pulmonary disease, e.g.,advanced hepatocellular carcinoma, end-stage renal failure, et al.)
- A terminal medical diagnosis consistent with survival < 1 year
- Diabetes mellitus, Hyperlipidemia, Metabolic syndrome, Heartfailure) ⑧ Pregnant or lactating women ⑨ Prohibited fromtaking medication (Omapone Peri 724mL or Winuf Peri 654mL)
Study Design
Total Participants: 97
Treatment Group(s): 1
Primary Treatment: Omapone Peri 724mL or Winuf Peri 654mL
Phase:
Study Start date:
January 29, 2020
Estimated Completion Date:
December 31, 2023
Connect with a study center
Samsung Medical Center
Seoul, 135-710
Korea, Republic ofSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.